{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:29:55Z","timestamp":1755797395305,"version":"3.40.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10620-024-08821-y","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T13:26:20Z","timestamp":1737984380000},"page":"1320-1327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study"],"prefix":"10.1007","volume":"70","author":[{"given":"Sailish","family":"Honap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Caron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob E.","family":"Ollech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Fischman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Papamichael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djuna","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina B.","family":"Gecse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Centritto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles P.","family":"Sparrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Karmiris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Chateau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the International Consortium for Therapeutic Drug Monitoring (spECTRUM)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"8821_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.dld.2022.08.039","volume":"55","author":"N Dai","year":"2023","unstructured":"Dai N, Haidar O, Askari A, Segal JP. Colectomy rates in ulcerative colitis: A systematic review and meta-analysis. Dig Liver Dis. 2023;55:13\u201320.","journal-title":"Dig Liver Dis."},{"key":"8821_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"CL Berre","year":"2023","unstructured":"Berre CL, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571\u2013584.","journal-title":"Lancet."},{"key":"8821_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/codi.13802","volume":"20","author":"A Mark-Christensen","year":"2018","unstructured":"Mark-Christensen A, Erichsen R, Brandsborg S et al. Pouch failures following ileal pouch-anal anastomosis for ulcerative colitis. Colorectal Dis. 2018;20:44\u201352.","journal-title":"Colorectal Dis."},{"key":"8821_CR4","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.cgh.2020.06.035","volume":"19","author":"EL Barnes","year":"2021","unstructured":"Barnes EL, Herfarth HH, Kappelman MD et al. Incidence, risk factors, and outcomes of pouchitis and pouch-related complications in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19:1583-1591.e4.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8821_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cgh.2022.04.015","volume":"21","author":"EL Barnes","year":"2023","unstructured":"Barnes EL, Allin KH, Iversen AT, Herfarth HH, Jess T. Increasing incidence of pouchitis between 1996 and 2018: a population-based danish cohort study. Clin Gastroenterol Hepatol. 2023;21:192-199.e7.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8821_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro F, Gionchetti P, Eliakim R et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649\u201370.","journal-title":"J Crohns Colitis."},{"key":"8821_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2023.10.015","volume":"166","author":"EL Barnes","year":"2024","unstructured":"Barnes EL, Agrawal M, Syal G et al. AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders. Gastroenterology. 2024;166:59\u201385.","journal-title":"Gastroenterology."},{"key":"8821_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","volume":"7","author":"K Papamichael","year":"2022","unstructured":"Papamichael K, Afif W, Drobne D et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022;7:171\u2013185.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"8821_CR9","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326:2375\u20132384.","journal-title":"JAMA."},{"key":"8821_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41395-018-0073-0","volume":"113","author":"B Ungar","year":"2018","unstructured":"Ungar B, Engel T, Yablecovitch D et al. Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: The POETIC study. Am J Gastroenterol. 2018;113:890\u2013898.","journal-title":"Am J Gastroenterol."},{"key":"8821_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/ibd\/izx049","volume":"24","author":"M Huguet","year":"2018","unstructured":"Huguet M, Pereira B, Goutte M et al. Systematic review with meta-analysis: anti-TNF therapy in refractory pouchitis and crohn\u2019s disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis. Inflamm Bowel Dis. 2018;24:261\u2013268.","journal-title":"Inflamm Bowel Dis."},{"key":"8821_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/apt.13905","volume":"45","author":"JP Segal","year":"2017","unstructured":"Segal JP, Ding NS, Worley G et al. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm. Alimentary Pharmacol Ther. 2017;45:581\u2013592.","journal-title":"Alimentary Pharmacol Ther."},{"key":"8821_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/00365521.2019.1569718","volume":"54","author":"MD Kj\u00e6r","year":"2019","unstructured":"Kj\u00e6r MD, Qvist N, Nordgaard-Lassen I, Christensen LA, Kjeldsen J. Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial. Scand J Gastroenterol. 2019;54:188\u201393.","journal-title":"Scand J Gastroenterol."},{"key":"8821_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cgh.2015.11.014","volume":"14","author":"K Papamichael","year":"2016","unstructured":"Papamichael K, Van Stappen T, Vande Casteele N et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:543\u2013549.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8821_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/apt.14458","volume":"47","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018;47:478\u2013484.","journal-title":"Aliment Pharmacol Ther."},{"key":"8821_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/ecco-jcc\/jjw122","volume":"11","author":"K Papamichael","year":"2017","unstructured":"Papamichael K, Baert F, Tops S et al. Post-induction Adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis. J Crohns Colitis. 2017;11:53\u201359.","journal-title":"J Crohns Colitis."},{"key":"8821_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MIB.0000000000000689","volume":"22","author":"AJ Yarur","year":"2016","unstructured":"Yarur AJ, Jain A, Hauenstein SI et al. Higher Adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn\u2019s disease and ulcerative colitis. Inflamm Bowel Dis. 2016;22:409\u2013415.","journal-title":"Inflamm Bowel Dis."},{"key":"8821_CR18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","volume":"17","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS, Melmed GY et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655-1668.e3.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8821_CR19","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1053\/j.gastro.2022.02.014","volume":"162","author":"PM Irving","year":"2022","unstructured":"Irving PM, Gecse KB. Optimizing therapies using therapeutic drug monitoring: current strategies and future perspectives. Gastroenterology. 2022;162:1512\u20131524.","journal-title":"Gastroenterology."},{"key":"8821_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1177\/2050640619871797","volume":"7","author":"B Verstockt","year":"2019","unstructured":"Verstockt B, Claeys C, De Hertogh G et al. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. United Eur Gastroenterol J. 2019;7:1215\u20131225.","journal-title":"United Eur Gastroenterol J."},{"key":"8821_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0025-6196(12)61634-6","volume":"69","author":"WJ Sandborn","year":"1994","unstructured":"Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis disease activity index. Mayo Clin Proc. 1994;69:409\u2013415.","journal-title":"Mayo Clin Proc."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08821-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:40:14Z","timestamp":1745487614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08821-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["8821"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08821-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH served as a speaker, a consultant, an advisory board member, and\/or has received travel grants from Pfizer, Janssen, AbbVie, Takeda, Ferring, Pharmacosmos, Banook Group, and Galapagos\/Alpha Sigma. BC has received lecture and\/or consulting fees from AbbVie, Amgen, Celltrion, Ferring, Galapagos, Janssen, Lilly, Pfizer, and Takeda. JEO reports institutional research grants from Pfizer. KP received lecture\/speaker fees from Physicians Education Resource LLC and Grifols; scientific advisory board fees from ProciseDx Inc and Scipher Medicine Corporation; and serves as a consultant for Prometheus Laboratories Inc. DJ has received speaker fee from Johnson and Johnson. KBG has received grants from Pfizer Inc., Galapagos, and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis, and Takeda; and speaker\u2019s honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts, all outside the submitted work. MAS has received personal fees from Takeda, Janssen, Sandoz, MSD, Falk, Samsung Bioepis, Galapagos, and Bristol Myers Squibb. PMI reports research grants from Celltrion, Pfizer Inc., Takeda Pharmaceutical Company, and Galapagos; consulting fees from AbbVie Inc., Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Elasmogen Ltd, Gilead Sciences Pty Ltd, Janssen Pharmaceuticals, Eli Lilly and Company, Pfizer Inc., Prometheus, and Sandoz; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie Inc., Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Galapagos, Gilead Sciences Inc., Janssen Pharmaceuticals, Eli Lilly and Company, Pfizer Inc., Takeda Pharmaceutical Company, and Tillotts Pharma AG; and support for attending meetings and\/or travel from AbbVie and Tillotts Pharma AG. MPS has received educational grants or research support from Ferring, Orphan, and Gilead; speaker\u2019s fees from Janssen, Abbvie, Ferring, Takeda, Pfizer, and Shire; and served on advisory boards for Janssen, Takeda, Pfizer, Celgene, Abbvie, MSD, and Emerge Health. KK has served as speaker, consultant and advisory board member for Abbvie, Amgen, Ferring, Galenica, Genesis, Janssen, MSD, Pfizer, Takeda, and Vianex ID has received consultation fees, research grants, or honoraria from Janssen, Pfizer, Abbvie, Takeda, Genentech\/Roche, Ferring, Iterative Scopes, Integra Holdings, Eli Lilly, Falk Pharma, Gilead, Galapagos, Celgene\/BMS, Arena, Sublimity, Sangamo, Sandoz, Celltrion, Abbott, Prometheus, Altman, and Athos; Shareholder: Harp Diagnostics and GUTREAT. LPB reports fees received from: AbbVie, Adacyte, Alimentiv, Alma Bio Therapeutics, Amgen, Applied Molecular Transport, Arena, Biogen, BMS, Celltrion, CONNECT Biopharm, Cytoki Pharma, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Gossamer Bio, GSK, HAC-Pharma, IAG Image Analysis, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Medac, Mopac, Morphic, MSD, Norgine, Nordic Pharma, Novartis, OM Pharma, ONO Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Par\u2019Immune, Pfizer, Prometheus, Protagonist, Roche, Sanofi, Sandoz, Takeda, Theravance, Thermo Fisher, Tigenix, Tillots, Viatris, Vifor, Ysopia, Abivax, Samsung, Ventyx, Roivant, and Vectivbio. The remaining authors have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}